Unusual clinical presentations of hairy cell leukemia
Acta Haematol. 2024 Jan 4. doi: 10.1159/000536043. Online ahead of print.NO ABSTRACTPMID:38176393 | DOI:10.1159/000536043 (Source: Acta Haematologica)
Source: Acta Haematologica - January 4, 2024 Category: Hematology Authors: Xavier Troussard Source Type: research
Unusual clinical presentations of hairy cell leukemia
Acta Haematol. 2024 Jan 4. doi: 10.1159/000536043. Online ahead of print.NO ABSTRACTPMID:38176393 | DOI:10.1159/000536043 (Source: Acta Haematologica)
Source: Acta Haematologica - January 4, 2024 Category: Hematology Authors: Xavier Troussard Source Type: research
Treatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience
Acta Haematol. 2023;146(6):490-495. doi: 10.1159/000533346. Epub 2023 Aug 9.ABSTRACTPatients living with HIV are now living longer due to increased access to antiretroviral therapy (ART) and a decrease in acquired immunodeficiency syndrome-defining cancer (ADC). However, increasing age and previous chemotherapy exposure for ADC (e.g., anthracyclines and topoisomerase inhibitors) are factors that may increase the risk of developing therapy-related myelodysplastic syndrome and acute myeloid leukemia (AML) and highlight an unmet need. There are no established guidelines for the treatment of AML in patients with HIV and the li...
Source: Acta Haematologica - December 29, 2023 Category: Hematology Authors: Jose Tinajero Dat Ngo Alfredo Puing Paul Koller Source Type: research
Treatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience
Acta Haematol. 2023;146(6):490-495. doi: 10.1159/000533346. Epub 2023 Aug 9.ABSTRACTPatients living with HIV are now living longer due to increased access to antiretroviral therapy (ART) and a decrease in acquired immunodeficiency syndrome-defining cancer (ADC). However, increasing age and previous chemotherapy exposure for ADC (e.g., anthracyclines and topoisomerase inhibitors) are factors that may increase the risk of developing therapy-related myelodysplastic syndrome and acute myeloid leukemia (AML) and highlight an unmet need. There are no established guidelines for the treatment of AML in patients with HIV and the li...
Source: Acta Haematologica - December 29, 2023 Category: Hematology Authors: Jose Tinajero Dat Ngo Alfredo Puing Paul Koller Source Type: research
Treatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience
Acta Haematol. 2023;146(6):490-495. doi: 10.1159/000533346. Epub 2023 Aug 9.ABSTRACTPatients living with HIV are now living longer due to increased access to antiretroviral therapy (ART) and a decrease in acquired immunodeficiency syndrome-defining cancer (ADC). However, increasing age and previous chemotherapy exposure for ADC (e.g., anthracyclines and topoisomerase inhibitors) are factors that may increase the risk of developing therapy-related myelodysplastic syndrome and acute myeloid leukemia (AML) and highlight an unmet need. There are no established guidelines for the treatment of AML in patients with HIV and the li...
Source: Acta Haematologica - December 29, 2023 Category: Hematology Authors: Jose Tinajero Dat Ngo Alfredo Puing Paul Koller Source Type: research
Treatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience
Acta Haematol. 2023;146(6):490-495. doi: 10.1159/000533346. Epub 2023 Aug 9.ABSTRACTPatients living with HIV are now living longer due to increased access to antiretroviral therapy (ART) and a decrease in acquired immunodeficiency syndrome-defining cancer (ADC). However, increasing age and previous chemotherapy exposure for ADC (e.g., anthracyclines and topoisomerase inhibitors) are factors that may increase the risk of developing therapy-related myelodysplastic syndrome and acute myeloid leukemia (AML) and highlight an unmet need. There are no established guidelines for the treatment of AML in patients with HIV and the li...
Source: Acta Haematologica - December 29, 2023 Category: Hematology Authors: Jose Tinajero Dat Ngo Alfredo Puing Paul Koller Source Type: research
Treatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience
Acta Haematol. 2023;146(6):490-495. doi: 10.1159/000533346. Epub 2023 Aug 9.ABSTRACTPatients living with HIV are now living longer due to increased access to antiretroviral therapy (ART) and a decrease in acquired immunodeficiency syndrome-defining cancer (ADC). However, increasing age and previous chemotherapy exposure for ADC (e.g., anthracyclines and topoisomerase inhibitors) are factors that may increase the risk of developing therapy-related myelodysplastic syndrome and acute myeloid leukemia (AML) and highlight an unmet need. There are no established guidelines for the treatment of AML in patients with HIV and the li...
Source: Acta Haematologica - December 29, 2023 Category: Hematology Authors: Jose Tinajero Dat Ngo Alfredo Puing Paul Koller Source Type: research
The Effect of The Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes A Study by the Israeli MDS Working Group
CONCLUSIONS: Herein we showed preliminary evidence that DFP decreases iron-induced oxidative stress in MDS patients with a good tolerability profile (albeit a short follow-up period). No cases of severe neutropenia or agranulocytosis were reported. The future challenge is to prove that reduction in iron toxicity will eventually be translated into a clinically meaningful improvement.PMID:38104534 | DOI:10.1159/000535749 (Source: Acta Haematologica)
Source: Acta Haematologica - December 17, 2023 Category: Hematology Authors: Drorit Merkel Shelly Soffer Kalman Filanovsky Andrei Braester Eitan Fibach Mutaz Dana Yishai Ofran Uri Greenbaum Arnon Nagler Irina Amitai Moshe Mittelman Source Type: research
The Effect of The Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes A Study by the Israeli MDS Working Group
CONCLUSIONS: Herein we showed preliminary evidence that DFP decreases iron-induced oxidative stress in MDS patients with a good tolerability profile (albeit a short follow-up period). No cases of severe neutropenia or agranulocytosis were reported. The future challenge is to prove that reduction in iron toxicity will eventually be translated into a clinically meaningful improvement.PMID:38104534 | DOI:10.1159/000535749 (Source: Acta Haematologica)
Source: Acta Haematologica - December 17, 2023 Category: Hematology Authors: Drorit Merkel Shelly Soffer Kalman Filanovsky Andrei Braester Eitan Fibach Mutaz Dana Yishai Ofran Uri Greenbaum Arnon Nagler Irina Amitai Moshe Mittelman Source Type: research
The Effect of The Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes A Study by the Israeli MDS Working Group
CONCLUSIONS: Herein we showed preliminary evidence that DFP decreases iron-induced oxidative stress in MDS patients with a good tolerability profile (albeit a short follow-up period). No cases of severe neutropenia or agranulocytosis were reported. The future challenge is to prove that reduction in iron toxicity will eventually be translated into a clinically meaningful improvement.PMID:38104534 | DOI:10.1159/000535749 (Source: Acta Haematologica)
Source: Acta Haematologica - December 17, 2023 Category: Hematology Authors: Drorit Merkel Shelly Soffer Kalman Filanovsky Andrei Braester Eitan Fibach Mutaz Dana Yishai Ofran Uri Greenbaum Arnon Nagler Irina Amitai Moshe Mittelman Source Type: research
The Effect of The Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes A Study by the Israeli MDS Working Group
CONCLUSIONS: Herein we showed preliminary evidence that DFP decreases iron-induced oxidative stress in MDS patients with a good tolerability profile (albeit a short follow-up period). No cases of severe neutropenia or agranulocytosis were reported. The future challenge is to prove that reduction in iron toxicity will eventually be translated into a clinically meaningful improvement.PMID:38104534 | DOI:10.1159/000535749 (Source: Acta Haematologica)
Source: Acta Haematologica - December 17, 2023 Category: Hematology Authors: Drorit Merkel Shelly Soffer Kalman Filanovsky Andrei Braester Eitan Fibach Mutaz Dana Yishai Ofran Uri Greenbaum Arnon Nagler Irina Amitai Moshe Mittelman Source Type: research
The Effect of The Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes A Study by the Israeli MDS Working Group
CONCLUSIONS: Herein we showed preliminary evidence that DFP decreases iron-induced oxidative stress in MDS patients with a good tolerability profile (albeit a short follow-up period). No cases of severe neutropenia or agranulocytosis were reported. The future challenge is to prove that reduction in iron toxicity will eventually be translated into a clinically meaningful improvement.PMID:38104534 | DOI:10.1159/000535749 (Source: Acta Haematologica)
Source: Acta Haematologica - December 17, 2023 Category: Hematology Authors: Drorit Merkel Shelly Soffer Kalman Filanovsky Andrei Braester Eitan Fibach Mutaz Dana Yishai Ofran Uri Greenbaum Arnon Nagler Irina Amitai Moshe Mittelman Source Type: research
The Effect of The Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes A Study by the Israeli MDS Working Group
CONCLUSIONS: Herein we showed preliminary evidence that DFP decreases iron-induced oxidative stress in MDS patients with a good tolerability profile (albeit a short follow-up period). No cases of severe neutropenia or agranulocytosis were reported. The future challenge is to prove that reduction in iron toxicity will eventually be translated into a clinically meaningful improvement.PMID:38104534 | DOI:10.1159/000535749 (Source: Acta Haematologica)
Source: Acta Haematologica - December 17, 2023 Category: Hematology Authors: Drorit Merkel Shelly Soffer Kalman Filanovsky Andrei Braester Eitan Fibach Mutaz Dana Yishai Ofran Uri Greenbaum Arnon Nagler Irina Amitai Moshe Mittelman Source Type: research
The Effect of The Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes A Study by the Israeli MDS Working Group
CONCLUSIONS: Herein we showed preliminary evidence that DFP decreases iron-induced oxidative stress in MDS patients with a good tolerability profile (albeit a short follow-up period). No cases of severe neutropenia or agranulocytosis were reported. The future challenge is to prove that reduction in iron toxicity will eventually be translated into a clinically meaningful improvement.PMID:38104534 | DOI:10.1159/000535749 (Source: Acta Haematologica)
Source: Acta Haematologica - December 17, 2023 Category: Hematology Authors: Drorit Merkel Shelly Soffer Kalman Filanovsky Andrei Braester Eitan Fibach Mutaz Dana Yishai Ofran Uri Greenbaum Arnon Nagler Irina Amitai Moshe Mittelman Source Type: research
The Effect of The Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes A Study by the Israeli MDS Working Group
CONCLUSIONS: Herein we showed preliminary evidence that DFP decreases iron-induced oxidative stress in MDS patients with a good tolerability profile (albeit a short follow-up period). No cases of severe neutropenia or agranulocytosis were reported. The future challenge is to prove that reduction in iron toxicity will eventually be translated into a clinically meaningful improvement.PMID:38104534 | DOI:10.1159/000535749 (Source: Acta Haematologica)
Source: Acta Haematologica - December 17, 2023 Category: Hematology Authors: Drorit Merkel Shelly Soffer Kalman Filanovsky Andrei Braester Eitan Fibach Mutaz Dana Yishai Ofran Uri Greenbaum Arnon Nagler Irina Amitai Moshe Mittelman Source Type: research
